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Summary. Feline infectious peritonitis viruses (FIPVs) are classified into type I
and type II serogroups. Here, we report that feline aminopeptidase N (APN), a
cell-surface metalloprotease on the intestinal, lung and kidney epithelial cells, is
a receptor for type II FIPV but not for type I FIPV. A monoclonal antibody (MAb)
R-G-4, which blocks infection of Felis catus whole fetus (fcwf-4) cells by type
II FIPV, was obtained by immunizing mice with fcwf-4 cells which are highly
susceptible to FIPV. This MAb also blocked infection of fcwf-4 cells by type II
feline enteric coronavirus (FECV), canine coronavirus (CCV), and transmissible
gastroenteritis virus (TGEV). On the other hand, it did not block infection by
type I FIPVs. MAb R-G-4 recognized a polypeptide of relative molecular mass
120–130 kDa in feline intestinal brush-border membrane (BBM) proteins. The
polypeptide possessed aminopeptidase activity, and the first 15 N-terminal amino
acid sequence was identical to that of the feline APN. Feline intestinal BBM
proteins and the polypeptide reacted with MAb R-G-4 (feline APN) inhibited the
infectivity of type II FIPV, type II FECV, CCV and TGEV to fcwf-4 cells, but did
not inhibit the infectivity of type I FIPVs.
Introduction
Feline infectious peritonitis virus (FIPV), family Coronaviridae, genus Corona-
virus, causes a chronic, progressive, immunologically mediated disease in domes-
tic and exotic cats. The family Coronaviridae is divided into 3 distinct antigenic
groups on the basis of sequence analysis of their genome and antigenic relation-
ships. One of these includes human respiratory coronavirus 229E (HCV-229E),
transmissible gastroenteritis virus (TGEV) of swine, porcine respiratory corona-
virus, canine coronavirus (CCV), and feline coronavirus (FCoV) [6, 26]. Feline
coronaviruses (FCoVs ) are divided into FIPV types I and II, and feline enteric
coronavirus (FECV) types I and II, on the basis of disease type; that is, whether
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it causes FIP, the ability of the viruses to proliferate in cell cultures, and the anti-
genic relationship to TGEV and CCV [23]. The type II strains of FIPV and FECV
appeared to be more closely related to CCV and TGEV, i.e., immunodominant
neutralization epitopes shared by the spike proteins of TGEV, CCV, and the type II
FCoV strains seem to be absent in the type I strains [13]. Recently, these findings
were confirmed by sequence analysis. The spike genes of type II FCoVs have
much closer similarity to those of TGEV and CCV than to the spike genes of type
I isolates [19, 20].
Viral infection requires binding of the viruses to cellular receptors. Free virus
receptors administered to organisms antagonize the endogenous virus receptors,
and suppress proliferation of the virus. Therefore, virus receptors have drawn
attention as potential anti-virus drugs, and have been identified for several viruses
[16]. The CD13 antigen, which is an important cell-surface marker of myelocytic
leukemia, has been widely used for immunophenotyping of leukemia [10]. The
CD13 antigen has been identified by gene cloning as the enzyme aminopeptidase
N (APN) [18]. CD13/APN is widely distributed in respiratory and digestive epi-
thelial cells and blood cells [14, 25]. The physiological functions of CD13/APN
differ depending on cell type. In the intestinal brush border membrane (BBM),
for example, CD13/APN cleaves N-terminal amino acids of small peptides in the
final steps of digestion, and helps absorption of peptides from the small intestine
[25]. In 1992, 2 study groups simultaneously reported that CD13/APN functions
as a cellular receptor for TGEV and HCV-229E [8, 31]. In 1993, it was reported
that CD13/APN also functions as a receptor of cytomegalovirus [28]. Although
TGEV and HCV-229E both use CD13/APN as a receptor, the former cannot use
the human APN as a receptor, and the latter cannot use the porcine APN, showing
species-specific receptor recognition [7, 17]. It has also been shown that FIPV
and CCV, which are antigenically close to TGEV, cannot use the porcine APN as
a receptor [9]. Recently, it was reported that mouse and hamster cells, which are
intrinsically nonsusceptible to FIPV, are infected with FIPV if transfected with
feline APN genes, showing that FIPV also uses CD13/APN as a receptor [29].
However, it has been shown that type II FIPV strain 79–1 146 can use the canine
APN as a receptor, while type I FIPV strain TN 406 cannot, suggesting that FIPV
receptors are heterogeneous consisting of types [2].
In the present study, we further characterized the roles of the feline APN as
an FIPV receptor. Our results showed that type II FIPV uses the feline APN as a
receptor, but it is not a receptor for type I FIPVs.
Materials and methods
Cell cultures
Felis catus fetus cells (fcwf-4), Crandell feline kidney cells (CrFK), swine testis cells (ST),
swine kidney cells (CPK), and African green monkey kidney cells (Vero) were grown in
Eagles’ minimum essential medium (MEM) containing 50% L-15 medium, 10% fetal calf
serum (FCS), 100 unt/ml penicillin and 100 mg/ml streptomycin. Human monocyte cells
(U937) were cultured in RPMI 1 640 medium containing 10% FCS and antibiotics as above.
The cells were maintained in a humidified 5% CO2 incubator at 37 ◦C.
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Viruses
FIPV strains 79–1 146, KU-2, Black and UCD-1, FECV strain 79–1 683, TGEV strain To-
163, and CCV strain 1–71 were used in this study. FIPV strain 79–1 146 (type II) was
supplied by Dr. M. C. Horzinek of State University Utrecht, The Netherlands. FIPV strain
KU-2 (type I) was isolated in our laboratory. FIPV strain Black (type I) was supplied by Dr.
J. K. Yamamoto of the University of Florida. FIPV strain UCD-1 (type I) was supplied by Dr.
N. C. Pedersen of the University of California, Davis. FECV strain 79–1 683 was supplied
by Dr. A. J. McKeirnan of Washington State University, Pullman. TGEV strain To-163 was
supplied by National Institute of Animal Health of Japan. CCV strain 1–71 was supplied by
Dr. E. Takahashi of the University of Tokyo, Japan.
FIPV and FECV, TGEV, and CCV were passaged two or three times in fcwf-4 cells,
CPK cells, and CrFK cells, respectively, and used in subsequent experiments.
Production of monoclonal anti-receptor antibody-secreting hybridoma
BALB/c mice, about 5 weeks of age, were inoculated intraperitoneally with a mixture of
1 × 106 fcwf-4 cells collected with a cell scraper and 1 × 109 cells of a pertussis adjuvant.
Two and four weeks after inoculation, a booster immunization with fcwf-4 cells alone was per-
formed, and spleen cells were collected 4 days after the last immunization. Fusion was carried
out essentially as described by Köhler and Milstein [15]. Polyethyleneglycol-4,000 (Merck,
Germany) was used as a fusing agent, and the ratio of mouse spleen cells to mouse myeloma
cells (P-3/I-63-Ag8-6, 5, 3) was 10: 1. Screening for anti-receptor antibody-secreting hy-
bridomas was carried out by examining blockade of infection of fcwf-4 cells by type II FIPV
strain 79–1 146. Antibody-secreting hybredoma colonies were cloned by limiting dilution
method.
Flow cytometric analysis
A total of 1 × 106 cells were incubated with anti-receptor MAb at 4 ◦C for 1 h. The cells
were washed three times in Hanks’ balanced salt solution (HBSS) containing 0.1% NaN3,
resuspended and incubated with fluorescein isothiocyanate (FITC)-conjugated Fab of goat
anti-mouse IgG antibody at 4 ◦C for 1 h. The cells were washed three times, and the number
of stained cells was determined by counting about 10 000 cells on a fluorescence-activated
cell sorter (FACS) 440 (Becton Dickinson).
Preparation of brush-border membrane proteins
Brush-border membrane proteins were purified according to the Booth and Kenny method [3].
The lumen of the small intestine of cats and pigs was washed with mannitol-Tris medium (10
mM mannitol, 2 mM Tris-HCl, pH 7.1), and microvilli were removed with a surgical blade.
The mannitol-Tris medium was added to the microvilli to 10% (W/V), and homogenized
with a blender. The total volume of the homogenate was 200 ml. Solid MgCl2, 6H2O was
added to the homogenate to a final concentration of 10 mM, and occasionally stirred on ice
for 15 min. The homogenate was centrifuged at 1 500 × g for 12 min, and the supernatant
thus obtained was further centrifuged at 15 000 × g for 12 min. The pale-pink layer above the
pellet was collected, and resuspended in 100 ml mannitol-Tris medium. MgCl2 was added to
the suspension to 10 mM, and gently stirred for 15 min. The suspension was centrifuged at
2 200 × g for 12 min, and the supernatant was further centrifuged at 15 000 × g for 12 min.
The pellet was resuspended in 100 ml mannitol-Tris medium.
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Purification of polypeptides recognized by the anti-recepter MAb
by affinity chromatography
Polypeptides recognized by the anti-receptor MAb were purified from feline intestinal BBM
proteins by affinity chromatography, using HiTrap NHS-Activated Affinity Colums (Pharma-
cia, Biotech, Sweden) according to the manufacturer’s protocol. As the ligand, IgG purified
from the culture fluid of anti-receptor MAb R-G-4 with protein A-sepharose CL-4B (Phar-
macia Biotech, Sweden) was used. The molecular weights of the purified polypeptides were
determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and
Coomassie blue staining.
Aminopeptidase enzyme activity
The aminopeptidase substrate L-leucyl P-nitroanilide was added at 2 mM to samples, and
allowed to react at 37 ◦C. After 30, 60, 120, and 180 min, the reaction was stopped by adding
0.15 M acetic acid, and the absorbance at 405 nm was measured.
Inhibition of the virus infectivity by BBM proteins or polypeptides recognized
by the anti-receptor MAb
The inhibitory effects of receptor proteins on virus infection were tested as follows. The same
amounts of a 10-fold dilution of BBM proteins and 200 PFU/0.1 ml of each virus strain were
mixed, and allowed to react at 4 ◦C for 2 h . Aliquots of 0.1 ml of the mixture were inoculated
into fcwf-4 cells cultured in 12-well plates, reacted at 37 ◦C for 1 h, then washed with HBSS,
and 2 ml of medium containing 1.5% carboxymethyl cellulose was added.
The cells were incubated in a CO2 incubator at 37 ◦C for 3 days, fixed in 10% buffered
formalin, and stained with 1% crystal violet. The number of plaques produced by the remain-
ing infectious virus was counted, and the degree of inhibition of each dilution was estimated
as compared with the same virus titer when mixed with HBSS.
N-terminal amino acid sequencing of the polypeptide recognized by MAb R-G-4
The polypeptide recognized by MAb R-G-4 was separated by SDS-PAGE, and transferred
onto a polyvinylidene difluoride (PVDF) membrane. PVDF membranes onto which were
transferred the antigenic polypeptides were stained with Coomassie brilliant blue R-250, and
the bands cut out. The N-terminal amino acid sequence was determined by APRO SCIENCE
Co., Ltd., Japan.
Results
To obtain MAbs against the FIPV receptor, we produced hybridomas against fcwf-
4 cells, a feline whole-fetus cell line highly susceptible to FIPV. A MAb which
blocked infection of fcwf-4 cells by type II FIPV strain 79–1 146 was obtained
and designated R-G-4. Table 1 shows the reactivity of the feline, porcine, human
and simian cell lines with the MAb R-G-4 and their susceptibility to FIPV, FECV,
CCV, and TGEV. MAb R-G-4 reacted to fcwf-4 and CrFK cells both derived
from feline cells, but not to ST, CPK, U937 or Vero cells derived from porcine,
human and simian cells. CrFK cells which were susceptible to FIPV strain 79–
1 146, FECV strain 79–1 683, CCV strain 1–71, and TGEV strain TO-163 were
nonsusceptible to type I FIPV strain KU-2, Black and UCD-1. We examined
whether infection of fcwf-4 cells by these 7 coronaviruses was blocked by the
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Table 1. Reactivity of feline, porcine, human and simian cell lines with the MAb R-G-4
and their susceptibility to coronaviruses
aCells were passaged if CPE was not detected after inoculation of viruses, and after 3
days, the virus-specific antigen was detected by indirect fluorescent antibody assay
bDetection by flow cytometry
cCPE and virus antigen-positive
dCPE and virus antigen-negative
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Fig. 1. Blocking of virus infection by the MAb R-G-4. The culture fluid of MAb R-G-4
secreting hybridoma or HBSS was added to fcwf-4 cells cultured in 12-well plates, and
incubated at 37 ◦C for 1 h. The cells were washed with HBSS, inoculated with about 100
PFU/0.1 ml of each virus, and incubated at 37 ◦C for 1 h. The cells were washed with HBSS,
then medium containing 1.5% corboxymethyl cellulose was added, and incubated at 37 ◦C
for 3 days. The cells were fixed with 10% buffered formalin, and stained with 1% crystal
violet, then the number of plaques was counted
MAb R-G-4. As shown in Fig. 1, MAb R-G-4 blocked infection by FIPV strain
79–1 146, FECV, CCV, and TGEV, but did not block that by KU-2, Black or
UCD-1 which are classified into type I FIPV.
By flow cytometric analysis, we examined whether binding of the MAb R-
G-4 to fcwf-4 cells was blocked by feline or porcine intestinal BBM proteins. As
shown in Fig. 2, the reactivity of MAb R-G-4 which had been preincubated with
porcine intestinal BBM proteins was not blocked as in the MAb R-G-4 which
had been reacted with HBSS. On the other hand, the reactivity of MAb R-G-4
which had been preincubated with feline intestinal BBM proteins was blocked,
and the peak was shifted closer to that of control cells. Therefore, we attempted
to purify polypeptides recognized by the MAb R-G-4 from feline intestinal BBM
proteins. Purification was performed using the MAb R-G-4 as the ligand by affinity
chromatography. As shown in lane 3 of Fig. 3, the MAb recognized a polypeptide
with a relative molecular mass of 120–130 kDa. The polypeptide was examined
for aminopeptidase activity using L-Leucyl P-nitroanilide as a substrate. As shown
in Fig. 4, the absorbance at 405 nm increased with time, and free P-nitroanilide
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Fig. 2. Flow cytometric analysis of the MAb R-G-4 binding to feline and porcine intestinal
brush-border membrane proteins. The MAb R-G-4 was mixed with HBSS (a), feline (b)
or porcine (c) intestinal brush-border membrane proteins, and allowed to react at 37 ◦C for
1 h. The mixture was added to 1 × 106 fcwf-4 cells, and allowed to react at 4 ◦C for 1 h.
After rinsing, FITC-conjugated Fab of goat anti-mouse IgG antibody was added, and the
number of stained cells was determined with FACS 440. — fcwf-4 cells treated with the
mixture; - - - control fcwf-4 cells (reacted with HBSS instead of the mixture)
Fig. 3. Polypeptide recognized by the anti-receptor MAb R-G-4.
Polypeptides recognized by the MAb R-G-4 were purified from feline
intestinal brush-border membrane proteins by affinity chromatography
using MAb R-G-4 as the ligand. 1 Marker proteins; 2 feline intestinal
brush-border membrane proteins; 3 polypeptide recognized by MAb
R-G-4
was detected. This enzyme activity was completely blocked by addition of the
inhibitor, 1, 10-phenanthroline or Bestatine (Fig. 4). The aminopeptidase activity
was not detected in the eluted fraction (data not shown). The first 15 amino acids of
the polypeptide were determined by N-terminal sequencing: NH2-Ala-Lys-Gly-
Phe-Tyr-Ile-Ser-Lys-Pro-Val-Ala-Ile-Leu-Ala-Ile-COOH. This sequence agreed
with the N-terminal sequence of feline aminopeptidase N at 93.3%.
The virus-binding capacities of feline and porcine intestinal BBM proteins or
the polypeptide recognized by the MAb R-G-4 were examined by neutralization
of the virus infectivity. Ten fold-diluted samples were reacted with 200 p.f.u. FIPV
strain 79–1 146, KU-2, Black, UCD-1, FECV strain 79–1 683, TGEV strain TO-
163 or CCV strain 1–71 at 4 ◦C for 2 h, and the amounts of infectious viruses in
the mixtures were determined by plaque assay. Feline intestinal BBM protein and
the polypeptide recognized by the MAb R-G-4 inhibited the infectivity of FIPV
strain 79–1 146, FECV strain 79–1 683, TGEV strain TO-163 and CCV strain
1–71. On the other hand, they did not inhibit the infectivity of the type I FIPV
strains KU-2, Black, and UCD-1 (Fig. 5a, c). The infectivity of all viruses tested,
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Fig. 4. Aminopeptidase activity of the polypeptide
recognized by MAb R-G-4. 0.03 mg/ml polypep-
tide recognized by the MAb R-G-4 was mixed
with the same amount of PBS (d), 3.0 M 1,
10-phenanthroline (s) or 0.1 mg/ml Bestatine
(u), and allowed to react at 37 ◦C for 1 h. An
aminopeptidase substrate, L-leucy1 P-nitroanilide,
was added to each misture, and after 30, 60, 120,
and 180 min, absorbance at 405 nm was measured
Fig. 5. Neutralization kinetics of coronaviruses by feline and porcine intestinal brush-border
membrane protein, or polypeptide recognized by MAb R-G-4. Feline intestinal brush-border
membrane protein (a), porcine intestinal brush-border membrane protein (b), or polypeptide
recognized by MAb R-G-4 (c) were mixed with FIPV strain 79–1 146 (d), KU-2 (s), Black
(u), UCD-1 (n), FECV strain 79–1 683 (m), TGEV strain TO-163 (r), or CCV strain 1–71
(j) and incubated at 4 ◦C for 2 h. The virus titers in the mixtures were plaque assayed on
fcwf-4 cells
FIPV strain 79–1 146, FECV strain 79–1 683, TGEV strain TO-163 and CCV
strain 1–71, was not inhibited by the eluted fraction which was not absorbed by
the affinity column with the MAb R-G-4 as the ligand (data not shown). In the
porcine intestinal BBM proteins, the infectivity of TGEV strain TO-163 alone
was inhibited (Fig. 5b).
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Discussion
We immunized mice with fcwf-4 cells which are highly susceptible to FIPV, and
obtained MAb R-G-4 against the FIPV receptor. This MAb completely blocked
the infectivity of type II FIPV strain 79–1 146, type II FECV strain 79–1 683,
CCV strain 1–71, and TGEV strain TO-163 to fcwf-4 cells. Type II FIPV is
serologically similar to type II FECV, CCV and TGEV, and the deduced amino
acid sequence of S protein shows 95.4% homology with type II FECV, 90.9%
homology CCV, and 80.9% homology TGEV [13, 19, 20]. It was reported that
in cats experimentally infected with TGEV or CCV, the virus proliferated in
the small intestine and caused asymptomatic infection [1, 24, 27]. The cellular
receptor of these viruses including type II FIPV has been shown to be CD13/
APN [2, 8, 29, 31]. The polypeptide recognized by the MAb R-G-4 which was
purified from feline intestinal BBM proteins had aminopeptidase activity, and
the first 15 N-terminal amino acid sequence was similar to that of feline APN.
This shows that the polypeptide recognized by the MAb R-G-4 was the feline
APN. However, MAb R-G-4 could not block infection of fcwf-4 cells by type I
FIPVs.
The feline and porcine intestinal BBM proteins purified according to the
Booth and Kenny method [3] had aminopeptidase activity which was inhibited
by 1, 10-phenanthrolin or Bestatine (data not shown). CD13/APN is expressed
at high levels in intestinal brush border membranes, and plays a role in the final
steps of digestion by cleaving small peptides preferentially after N-terminal neu-
tral amino acids. Feline intestinal BBM proteins and polypeptides recognized by
the MAb R-G-4 which had been purified from the feline intestinal BBM proteins
inhibited the infectivity of type II FIPV, type II FECV, CCV, and TGEV, but not
of type I FIPVs. It was reported that TGEV can use the feline and canine APN
as a receptor, but FIPV and CCV cannot use the porcine APN as a receptor [9].
This agrees with the observation that the infectivity of FIPVs, FECV, and CCV
was not inhibited by porcine intestinal BBM proteins. MAb R-G-4 blocked the
infectivity of TGEV toward fcwf-4 cells, but not that of TGEV toward porcine
ST and CPK cells (data not shown). MAb R-G-4 reacted with feline fcwf-4
and CrFK cells, but did not react with feline ST or CPK cells. It was sug-
gested that the MAb R-G-4 recognized the antigenic domain specific to the feline
APN.
Tresnane et al. reported that both type I FIPV and type II FIPV infected feline
APN-transfected hamster cells [29]. However, in the present study: 1) The MAb
R-G-4 blocked infection of fcwf-4 cells by type II FIPV strain 79–1 146, but did
not block infection by type I FIPVs; 2) MAb R-G-4 recognized the feline APN; 3)
CrFK cells which reacted with MAb R-G-4 were infected by type II FIPV, but not
by type I FIPVs; and 4) Feline intestinal BBM proteins with the aminopeptidase
activity and polypeptides recognized by the MAb R-G-4 inhibited the infectivity
of type II FIPV, but not of type I FIPVs. These results showed that type II FIPV
uses the feline APN as a receptor, but it is not a receptor for type I FIPVs. In
the experiment by Tresnan et al., the infection rate of type I FIPV to feline
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APN-transfected hamster cells was much lower than that of type II FIPV (2%
and 30%, respectively) [29]. Benbacer et al. showed that type II FIPV can use the
canine APN as a receptor but type I FIPV cannot, supporting our results [2]. The
amino acid sequences of S proteins of type I and type II FIPVs showed obly about
46% homology [20], which may have been responsible for the differences in the
receptor between these FIPVs. The homology in the N-terminal 700 amino acids
of S proteins is very low, and there are few domains where the sequence of 5–6
consecutive amono acids is maintained. Neither type I nor type II FIPVs infected
porcine ST or CPK cells. However, Woods et al. showed that type I FIPV strain
UCD-1 infected newborn pigs [30]. This result suggested that strain UCD-1 may
use receptor proteins other than the APN because FIPV cannot use the porcine
APN as receptors. It has not been verified whether type II FIPV infects newborn
pigs, or whether proteins other the APN can be used as receptors. However, the
study by Woods et al. [30] supports our observation that type I FIPV does not use
the APN as a receptor unlike type II FIPV.
We previously reported that in the phylogenetic tree of the M and N protein-
deduced amino acid sequences, type I and type II FIPVs belong to the same group
as type II FECV, and these viruses are evolutionarily distant from CCV and TGEV.
In the phylogenetic tree of the S protein-deduced amino acid sequences, however,
type I FIPV strains form a group, which is very distant from the type II FIPV, type
II FECV, CCV, and TGEV groups [20]. In the present study, we demonstrated that
type II FIPV, type II FECV, CCV, and TGEV form a group because these viruses
use CD13/APN as a receptor, while type I FIPV alone uses a different receptor,
indicating that it is distant from those groups. Although the receptor binding site
of FIPV is unknown, there are important antigenic domains in S proteins such
as the neutralization and enhancement sites [4, 5, 11–13, 21, 22]. Generally, the
distribution of cells expressing virus receptors is an important factor determining
in viro proliferation of viruses (pathogenicity). Although type I and type II FIPVs
use different receptors, these FIPVs cause the same diseases because FIP is likely
immune-mediated and not directly related to virus replication. It is hoped that the
receptor (CD13/APN) binding site of type II FIPV and the cellular receptor of
type I FIPV will be identified in the near future.
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